Trials / Terminated
TerminatedNCT01933022
A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease
An Exploratory, Open Label, Single-arm Study to Evaluate the Effect of Eligard® 6-month on Biomarkers of Disease in Patients With Metastatic Prostate Cancer
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Astellas Pharma Europe Ltd. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the effect of the study medication (Eligard®) on cancer markers (in the blood) of prostate cancer.
Detailed description
The main objective of the study is to explore the effect of Eligard® on the following prostate cancer biomarkers: Testosterone in serum, Prostate Specific Antigen (PSA) in serum, Prostate Cancer Antigen (PCA3 score) in urine, PSA mRNA in blood/Peripheral Blood Mononuclear Cell (PBMC), PCA3 mRNA in blood/PBMC, Transmembrane protease, serine 2-Ets Related Gene (TMPRSS2-ERG) mRNA in blood/PBMC A blood sample for RNA analysis will also be collected and stored for future investigation in patients giving specific informed consent.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eligard | Subcutaneous Injection |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2013-08-30
- Last updated
- 2017-03-09
Locations
3 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT01933022. Inclusion in this directory is not an endorsement.